Publicaciones destacadas

• Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

  Villacampa, G; Tung, NM; Pernas, S; Paré, L; Bueno-Muiño, C;

  (...)

  Carey, LA; Mittendorf, EA; Martín, M; Prat, A; Tolaney, SM.

  Ver listado completo de autores

  Referencia:

  Annals Of Oncology 2023.

• An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)

  Prat, A; Bardia, A; Curigliano, G; Hammond, MEH; Loibl, S;

  Tolaney, SM; Viale, G.

  Referencia:

  Jama Oncology 2022.

• Customizing local and systemic therapies for women with early breast cancer: the st. gallen international consensus guidelines for treatment of early breast cancer 2021

  H J Burstein; G Curigliano; B Thürlimann; W P Weber; P Poortmans 5;

  M M Regan; H J Senn; E P Winer; M Gnant; Panelists of the St Gallen Consensus Conference.

  Referencia:

  Ann Oncol. 2021.

• A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

  Prat, A; Guarneri, V; Paré, L; Griguolo, G; Pascual, T;

  (...)

  Piacentini, F; D'Amico, R; Tagtiapco, E; Parker, JS; Conte, P.

  Ver listado completo de autores

  Referencia:

  Lancet Oncology 2020.

• Frequency and spectrum of PIK3CA somatic mutations in breast cancer

  Martínez-Sáez, O; Chic, N; Pascual, T; Adamo, B; Vidal, M;

  (...)

  Galván, P; Rodríguez, AB; Martinez, A; Muñoz, M; Prat, A.

  Ver listado completo de autores

  Referencia:

  Breast Cancer Research 2020.

• Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

  Brasó-Maristany, F; Griguolo, G; Pascual, T; Paré, L; Nuciforo, P;

  (...)

  Gomis, RR; Villagrasa, P; Cortés, J; Ciruelos, E; Prat, A.

  Ver listado completo de autores

  Referencia:

  Nature Communications 2020.

• Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

  Prat, A; Saura, C; Pascual, T; Hernando, C; Muñoz, M;

  (...)

  López, R; Céliz, P; Ciruelos, E; Villagrasa, P; Gavilá, J.

  Ver listado completo de autores

  Referencia:

  Lancet Oncology 2020.